Discovery of PDE2A inhibitors to treat memory deficits in mild cognitive impairment and alzheimer's disease
Ended Project Grant Awarded Last action
- Award ID
- R43AG071045
- Recipient
-
FD Neurotechnologies Consulting & Services, Inc. UEI MBHYJCHP8BQ7
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,499,270
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Funding
-
- $999,486.34 Federal
- $499,784.00 Non-federal
- Place of performance
- Columbia, MD 21046, USA
Award details come from USAspending.gov.
Description
- Abstract
- Despite the fact that more than 50% of early stage of alzheimer's disease (ad) patients with mild cognitive impairment (MCI) will progress to dementia within 5 years, current therapies provide minimal symptomatic relief, without curing or halting disease progression. Phosphodiesterase-2A (PDE2A), the most prevalent of pdes expressed in the cortex, hippocampus and amygdala, regions involved in cognitive impairment, has emerged as a promising target for the treatment of mild cognitive impairment without side effects. Despite promising preclinical data showing that some inhibitors of PDE2A inhibitors, such as BAY 60-7550 and ND 7001, enhance memory in animal models of ad, clinical studies have not advanced, due in part, to the low selectivity, poor metabolic stability and brain penetrance of available compounds. The broad, long-term goal of this project is to discover and develop novel inhibitors of PDE2A for the treatment of MCI. To streamline the exciting project toward a clinical candidate, we have assembled a team with expertise in medicinal chemistry and drug discovery and PDE-related pharmacology and pharmacokinetics. The complementary collaboration among FD neurotechnologies (DR. FU DU), university at buffalo (DRS. Ying XU and james m. O'donnell), and university of arizona (DR. WEI wang) will synergize the effort by utilizing state-of-the-art drug discovery tools and techniques to discover and optimize novel and drug-like inhibitors of PDE2A and to evaluate their pharmacological effects in cell and animal models.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$82 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $499,784 | $0 | |
| Original award | $499,784 | $499,784 |
Quick answers
Who received award R43AG071045?
R43AG071045 was awarded to FD Neurotechnologies Consulting & Services, Inc. by National Institute on Aging (National Institutes of Health) on September 1, 2021.
How much is award R43AG071045 worth?
$1,499,270 has been obligated on R43AG071045: $999,486 in federal funding and $499,784 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award